We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$647M
AUM Growth
-$194M
Cap. Flow
+$33.7M
Cap. Flow %
5.2%
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$20.4M
2
NKTR icon
Nektar Therapeutics
NKTR
+$14.1M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$8.7M
4
ESPR
Esperion Therapeutics
ESPR
+$6.56M
5
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
+$4.27M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12M
2
BIIB icon
Biogen
BIIB
+$8.66M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$3.63M
4
COGT icon
Cogent Biosciences
COGT
+$3.16M
5
INCY icon
Incyte
INCY
+$2.77M

Sector Composition

Rank Sector Weight
1 Miscellaneous 73.46%
2 Healthcare 26.22%
3 Consumer Staples 0.17%
4 Financials 0.05%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRS
76
PUT
DELISTED
Amyris Inc.
AMRS
$633K 0.1%
990
-1,831
-65% -$11K
AIM
77
AIM ImmunoTech
AIM
$8.05M
$620K 0.1%
+441
New +$645K
FOLD
78
DELISTED
Amicus Therapeutics
FOLD
$599K 0.09%
38,344
-26,566
-41% -$402K
CRDF icon
79
Cardiff Oncology
CRDF
$108M
$578K 0.09%
+125,092
New +$2.09M
ZGNX
80
PUT
DELISTED
Zogenix, Inc.
ZGNX
$561K 0.09%
127
-560
-82% -$23.1K
RSLS
81
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
$542K 0.08%
+1,682
New +$1.44M
DBVT
82
CALL
DBV Technologies
DBVT
$740M
$534K 0.08%
28
+2
+8% +$451
VIRX
83
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$488K 0.08%
66
+26
+65% +$2.31K
NURO
84
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$451K 0.07%
4,299
-4,581
-52% -$505K
ARAV
85
DELISTED
Aravive, Inc. Common Stock
ARAV
$447K 0.07%
36,767
-80,294
-69% -$827K
OPGN
86
DELISTED
OpGen, Inc
OPGN
$431K 0.07%
61
-69
-53% -$555K
CHEKZ
87
DELISTED
Check-Cap Ltd. Series C Warrant
CHEKZ
$428K 0.07%
+628,846
New +$489K
INSM icon
88
Insmed
INSM
$26B
$421K 0.07%
17,800
+4,500
+34% +$116K
MBOT icon
89
Microbot Medical
MBOT
$97.4M
$366K 0.06%
32,979
-50,314
-60% -$612K
BNBX
90
DELISTED
BNB PLUS CORP
BNBX
– –
-1
Closed -$867K
AMRN
91
PUT
Amarin Corp
AMRN
$293M
$343K 0.05%
55
– –
ISEE
92
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$332K 0.05%
+1,217
New +$3.36K
SIOX
93
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$331K 0.05%
+18,313
New +$270K
PHIO icon
94
Phio Pharmaceuticals
PHIO
$12M
$325K 0.05%
+28
New +$414K
NVIV
95
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$288K 0.04%
+226
New +$1.24M
ATEC icon
96
Alphatec Holdings
ATEC
$1.66B
$281K 0.04%
+94,216
New +$334K
XTIA icon
97
XTI Aerospace
XTIA
$37M
– –
0
– –
MBAI
98
MBody AI Ltd. Ordinary Share
MBAI
$8.75M
$264K 0.04%
465
+420
+933% +$308K
CYTO
99
DELISTED
Altamira Therapeutics Ltd
CYTO
$206K 0.03%
33
-10
-23% -$106K
CARM
100
PUT
DELISTED
Carisma Therapeutics
CARM
$196K 0.03%
+50
New +$2.2K
2 3
4
5 6

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $33.7M of net new capital in Q2 2018, opening 51 new positions and adding to 38 existing holdings. Its largest new stake was Novo Nordisk: 858,710 shares worth $19.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 83% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Biogen, an estimated $8.66M trimmed.

  • Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
  • Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
  • Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
  • Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
  • Sabby Management opened 51 new positions and closed 71 in Q2 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.